Publications

Authors:

Solito, Arianna; Bozzi Cionci, Nicole; Calgaro, Matteo; Caputo, Marina; Vannini, Lucia; Hasballa, Iderina; Archero, Francesca; Giglione, Enza; Ricotti, Roberta; Walker, Gillian Elisabeth; Petri, Antonella; Agosti, Emanuela; Bellomo, Giorgio; Aimaretti, Gianluca; Bona, Gianni; Bellone, Simonetta; Amoruso, Angela; Pane, Marco; Di Gioia, Diana; Vitulo, Nicola; Prodam, Flavia

Title:

Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial

Year:

2021

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

CLIN NUTR

ISSN of journal:

0261-5614

N° Volume:

40

Number or Folder:

7

Page numbers:

4585-4594

Keyword:

Insulin sensitivity; Microbiota; Pediatric obesity; Probiotics; Adolescent; Child; Cross-Over Studies; Double-Blind Method; Female; Gastrointestinal Microbiome; Humans; Insulin; Male; Pediatric Obesity; Probiotics; Treatment Outcome; Bifidobacterium breve; Insulin Resistance

Short description of contents:

Background & aims: Variations in gut microbiota might impact metabolism leading to body weight excess. We assessed the impact of a probiotic supplementation in pediatric obesity on weight, metabolic alterations, selected gut microbial groups, and functionality.Methods: Cross-over, double-blind, randomized control trial (BIFI-OBESE trial; NCT03261466). 101 youths (6-18 years, Tanner stage >= 2) with obesity and insulin-resistance on diet were randomized to 2 x 10(9) CFU/AFU/day of Bifidobacterium breve BR03 (DSM 16604) and B. breve B632 (DSM 24706) (51) or placebo (50) for 8 weeks with a 4-weeks wash-out period.Results: All subjects (M/F 54/47) completed the first 8 weeks, and 82 (M/F 43/39) the last part without adverse events. Mixed-effects models revealed a carry-over effect on many variables in the entire study, narrowing the analysis to the first 8 weeks before the wash-out periods. All subjects improved metabolic parameters, and decreased weight and Escherichia coli counts. Probiotics improved insulin sensitivity at fasting (QUICKI, 0.013 CI95%0.0-0.03) and during OGTT (ISI, 0.654 CI95%-0.11-1.41). Cytokines, GLP1, and target microbial counts did not vary. Of 25 SCFAs, acetic acid and acetic acid pentyl-ester relative abundance remained stable in the probiotics, while increased in the placebo (p < 0.02). A signature of five butanoic esters identified three clusters, one of them had better glucose responses during probiotics.Conclusion: An 8 weeks treatment with B. breve BR03 and B632 had beneficial effects on insulin sensitivity in youths with obesity. Microbiota functionality could influence metabolic answers to probiotics. Long-term studies to confirm and enrich our findings are justified. Tailored probiotic treatments could be an additional strategy for obesity. (C) 2021 The Author(s). Published by Elsevier Ltd.

Product ID:

125331

Handle IRIS:

11562/1060201

Last Modified:

November 15, 2022

Bibliographic citation:

Solito, Arianna; Bozzi Cionci, Nicole; Calgaro, Matteo; Caputo, Marina; Vannini, Lucia; Hasballa, Iderina; Archero, Francesca; Giglione, Enza; Ricotti, Roberta; Walker, Gillian Elisabeth; Petri, Antonella; Agosti, Emanuela; Bellomo, Giorgio; Aimaretti, Gianluca; Bona, Gianni; Bellone, Simonetta; Amoruso, Angela; Pane, Marco; Di Gioia, Diana; Vitulo, Nicola; Prodam, Flavia, Supplementation with Bifidobacterium breve BR03 and B632 strains improved insulin sensitivity in children and adolescents with obesity in a cross-over, randomized double-blind placebo-controlled trial «CLIN NUTR» , vol. 40 , n. 7 , 2021 , pp. 4585-4594

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo